Keyword: H. Lundbeck

The takeover centers on a near-approval anti-CGRP antibody that could address Lundbeck’s need for near-term revenue drivers.

The deal will give Lundbeck a phase 2a Tourette's syndrome program, a CNS drug discovery platform and a West Coast research hub.

The data give Lundbeck a boost at a time when its recently installed CEO is hunting for ways to improve on lackluster growth forecasts.

The setback to the mooted blockbuster wiped around 30% off Lundbeck’s stock price.

Kyowa Hakko Kirin has posted a look at proof-of-concept data on adenosine A2A receptor antagonist KW-6356 in early Parkinson’s disease patients.

The buyout gives Lundbeck control of an mGluR4 positive allosteric modulator designed to improve the long-term symptom control of dopaminergic agents.

Lundbeck chief Schultz will lead Teva, former CDC director Frieden leads a new health project, Roivant named Eisai exec Waxman as general counsel.

Merck has halted a phase 2/3 Alzheimer’s disease trial after an interim analysis found it was destined to fail.

Lundbeck is calling time on development of Alzheimer’s candidate idalopirdine after it chalked up a clean sweep of failures in phase 3.

Lundbeck has struck a deal with Ossianix to use shark-derived antibodies to hustle drugs across the blood-brain barrier.